Aubrey Schock, MD
Family Medicine · Daytona Beach, FLNPI 1801858105
Payments from drug & device makers
Across 175 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$585
- AstraZeneca$340
- GSK$317
- AbbVie$305
- Pfizer$292
- Abbott$249
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,283100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $585 |
| AstraZeneca | 20 | $340 |
| GSK | 18 | $317 |
| AbbVie(2 entities) | 17 | $305 |
| Pfizer | 15 | $292 |
| Abbott | 14 | $249 |
| Lilly USA, LLC | 8 | $139 |
| Bayer | 8 | $138 |
| Amgen | 6 | $107 |
| Astellas Pharma US Inc | 4 | $101 |
| Renalytix AI, Inc. | 3 | $64 |
| Merck | 4 | $56 |
| Exact Sciences | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Johnson & Johnson(2 entities) | 3 | $50 |
| Eisai Inc. | 3 | $50 |
| Scilex Pharmaceuticals Inc. | 1 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Averitas Pharma Inc. | 1 | $28 |
| Medtronic | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$114
How this compares
$3,283 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $93,801 |
| EliquisApixaban | 88 | $88,186 |
| JardianceEmpagliflozin | 26 | $41,118 |
| XareltoRivaroxaban | 37 | $40,190 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $39,374 |
| JanuviaSitagliptin Phosphate | 14 | $21,596 |
| MounjaroTirzepatide | 14 | $15,361 |
| EntrestoSacubitril/Valsartan | 14 | $14,750 |
| MyrbetriqMirabegron | 15 | $11,149 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,143 |
| SynthroidLevothyroxine Sodium | 53 | $6,042 |
| Atorvastatin Calcium | 435 | $5,221 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $4,865 |
| Levothyroxine Sodium | 378 | $3,892 |
| Omeprazole | 223 | $3,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $585 | $93,80198 claims |
| PfizerEliquis, Paxlovid | $292 | $91,002109 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $317 | $48,51768 claims |
| Boehringer IngelheimJardiance | $30 | $41,11826 claims |
| Johnson & JohnsonXarelto | $50 | $40,19037 claims |
| MerckJanuvia | $56 | $21,59614 claims |
| Lilly USA, LLCMounjaro | $139 | $15,36114 claims |
| NovartisEntresto | $16 | $14,75014 claims |
| Astellas Pharma US IncMyrbetriq | $101 | $11,14915 claims |
| AbbVieSynthroid | $305 | $6,04253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Daytona Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.